Highlights

  • Cogstate Limited (ASX:CGS) reported FY26 revenue of USD 60.9 million, an increase of 15%.
  • FY26 EBITDA reached USD 18.3 million and net profit after tax was USD 11.9 million.
  • New clinical trial contracts totalled USD 89.0 million in FY26, up 116%.
  • Contracted future revenue reached USD 118.5 million, including USD 48.3 million scheduled for FY27.

Cogstate Limited (ASX:CGS) provides computerised cognitive assessments, clinical trial endpoint measurement and data-quality services for neuroscience drug development and healthcare. Its FY26 results documented higher recognised revenue, an expanded clinical trial portfolio and investment plans for artificial intelligence-enabled operations. In the 20 October 2026 trading session, Cogstate shares were reported at AUD 3.53, up 0.86% for the day. That market quotation is distinct from the company’s August financial disclosures.

Company Business

Cogstate operates principally through Clinical Trials and Healthcare activities. Clinical Trials customers use cognitive testing, central rating, scientific consultation and electronic clinical outcome assessment tools in research involving neurological and psychiatric conditions. The healthcare offering includes digital measures designed to assist practitioners in assessing cognitive function.

The business serves pharmaceutical and biotechnology sponsors internationally. Cogstate Limited (ASX:CGS) supports studies across Alzheimer’s disease, mood disorders, sleep conditions, rare diseases and other clinical indications. Its technology and services address consistency in patient assessment, data capture and interpretation across different research locations. Revenue from individual clinical trial contracts is recognised as milestones are delivered, rather than when the entire contract is signed.

Recent Development

In August 2026, Cogstate reported 90 new clinical trial starts during FY26, compared with 35 in FY25. The number of trials under way reached 171 at 30 June 2026, compared with 110 a year earlier. The active portfolio included 78 phase 2 studies and 42 phase 3 studies. The company attributed increased activity to work across several central nervous system indications.

Cogstate Limited (ASX:CGS) also outlined a two-year programme spanning FY27 and FY28 to develop AI-enabled rater training, central monitoring and other workflow functions. Management described most of the investment as capital expenditure. These initiatives concern internal clinical trial delivery processes; the company has not presented them as completed savings or guaranteed margin improvements.

Financial Performance and Sector Context

For the year ended 30 June 2026, Cogstate reported revenue of USD 60.9 million, up 15% from USD 53.1 million in FY25. Gross profit was USD 35.4 million, compared with USD 32.4 million, while gross margin decreased from 61% to 58%. EBITDA increased to USD 18.3 million from USD 16.0 million, and the EBITDA margin was unchanged at 30%.

Net profit before tax reached USD 16.1 million, up 16%, while net profit after tax increased 17% to USD 11.9 million. Cogstate Limited (ASX:CGS) reported USD 34.8 million of net cash and no debt in its FY26 investor briefing. Second-half EBITDA margin was 35%, compared with 24% in the first half, reflecting a different revenue and cost mix during the year.

New sales contracts totalled USD 89.0 million, versus USD 41.3 million in FY25. At 30 June 2026, contracted future revenue stood at USD 118.5 million, an increase of 32%. Of that amount, USD 48.3 million was expected to be recognised in FY27. Contract values and backlog are not equivalent to revenue already earned; recognition depends on trial progress and contract milestones.

The relevant operating environment is clinical research spending on central nervous system therapies. Sponsors’ programme timing, patient enrolment and study design affect demand and the pace of service delivery. Cogstate reported that contracts associated with channel partners represented approximately 40% of new contract value during FY26.

Risks to Consider

Clinical study delays, cancellations and slower patient recruitment could affect the timing of contracted revenue. Mix changes between software licensing, central rating and services may influence margins. Cogstate Limited (ASX:CGS) also faces implementation and expenditure risks as it develops its AI-enabled operating platform, while competition, customer budgets and data-quality requirements remain relevant to contract awards.

What to Watch Next

Key FY27 indicators include conversion of the USD 48.3 million contracted revenue amount into recognised sales, new contracts, ongoing trial counts and operating margins. Management expects revenue growth but links the outcome to the timing and value of additional contracts. It also anticipates a greater contribution from the June 2027 half than the December 2026 half.

Updates from Cogstate Limited (ASX:CGS) on AI workflow development, capital spending and deployment progress will provide evidence of how the investment programme is proceeding. The August briefing also disclosed a fully franked annual dividend of AUD 0.04 per share, paid in September 2026.

Key Insights

Cogstate closed FY26 with higher revenue and earnings, a larger clinical trial portfolio and an expanded contracted revenue base. Its FY27 performance will depend on converting research activity into recognised revenue while managing delivery costs and platform investment. These operational measures provide a clearer basis for monitoring progress than attributing short-term share price changes to earlier company announcements.